A5008649645- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Metastasis and carcinoma case studies
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Genetic Associations and Epidemiology
- Cancer-related Molecular Pathways
- Fungal Infections and Studies
- Cancer Research and Treatments
- Bone health and treatments
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Metabolism, Diabetes, and Cancer
- Glycosylation and Glycoproteins Research
University Hospital Ulm
2016-2025
Universität Ulm
2016-2024
Klinik für Frauenheilkunde
2012-2024
Heinrich Heine University Düsseldorf
2009-2024
Düsseldorf University Hospital
2007-2024
Universitäts Frauenklinik
2006-2024
Ludwig-Maximilians-Universität München
2013-2023
LMU Klinikum
2008-2020
University Hospital Heidelberg
2007-2019
University Medical Center Hamburg-Eppendorf
2007-2019
Abstract Purpose: The CellSearch system (Veridex, Warren, NJ) is designed to enrich and enumerate circulating tumor cells (CTCs) from peripheral blood. Here, we validated the analytic performance of this for clinical use in patients with metastatic breast cancer. Experimental Design: This prospective multicenter study conducted at three independent laboratories involved samples 92 Intra- inter-assay variability using controls containing defined numbers (average, 50 1,000, respectively), cell...
Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing patients. We assessed frequency mutations 17 predisposition genes, including BRCA1 and BRCA2, a large cohort patients with triple-negative (TNBC) unselected family history or ovarian determine utility those TNBC. Patients Methods TNBC (N = 1,824) were recruited through 12 studies, was sequenced identify mutations. Results Deleterious identified 14.6%...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
Abstract Introduction MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for first time, feasibility and clinical utility circulating miRs as biomarkers detection staging Methods The relative concentrations cancer-associated miR10b, miR34a, miR141 miR155 were measured in blood serum 89 patients with primary cancer (M0, n = 59) metastatic disease (M1, 30), 29 healthy women by a TaqMan...
Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in peripheral blood patients with metastatic breast cancer, less is available for CTCs at time primary diagnosis.We conducted a pooled analysis individual data from 3,173 nonmetastatic (stage I-III) cancer five institutions. The prevalence and numbers were assessed diagnosis FDA-cleared CellSearch System (Janssen Diagnostics, LLC). Patient outcomes analyzed using meta-analytic procedures,...
We aimed to determine the prognosis of patients with breast cancer diagnosed during pregnancy (BCP).In this cohort study, a multicentric registry BCP (from Cancer in Pregnancy, Leuven, Belgium, and GBG 29/BIG 02-03) compiled pro- retrospectively between 2003 2011 was compared who did not have associated pregnancies, using an age limit 45 years. Patients diagnosis postpartum were excluded. The main analysis performed Cox proportional hazards regression disease-free survival (DFS) overall (OS)...
Abstract Several hundred clinical trials currently explore the role of circulating tumor cell ( CTC ) analysis for therapy decisions, but assays are lacking comprehensive molecular characterization s with diagnostic precision. We therefore combined a workflow enrichment and isolation pure CTCs non‐random whole genome amplification method single cells applied it to 510 189 leukocytes 66 ‐positive breast cancer patients. defined integrity index GII identify suited by different assays, such as...
The prognostic significance of disseminated tumor cells (DTC) in bone marrow (BM) breast cancer patients at the time primary diagnosis has been confirmed by a large pooled analysis. In view lack early indicators for secondary adjuvant treatment, we here evaluated whether persistence DTCs after therapy increases risk subsequent relapse and death.Individual patient data from 676 women with stages I-III 3 follow-up studies were pooled. During clinical follow-up, underwent BM aspiration (BMA) to...
As the available information about breast cancer is growing every day, decision-making process for therapy getting more complex. ChatGPT as a transformer-based language model possesses ability to write scientific articles and pass medical exams. But it able support multidisciplinary tumor board (MDT) in planning of patients with cancer?
Abstract Background The phenotypes of tumor cells change during disease progression, but invasive rebiopsies metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative breast cancer (MBC) patients with HER2-positive circulating (CTCs) benefit from a HER2-targeted therapy. Methods open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited March 2012 until...
Abstract Purpose: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with selective binding to activatory Fcγ type I/III receptors, resulting in the formation of a tri-cell complex between tumor cells, T accessory cells. Patients metastatic breast cancer were enrolled into multicenter phase I dose-escalating trial. Experimental Design: Three ascending doses ertumaxomab (10-200 μg) administered i.v. on day 1, 7 ± 13 1. Safety tolerability primary objectives. Secondary...
Abstract Introduction There is a multitude of assays for the detection circulating tumor cells (CTCs) but very limited number studies comparing clinical relevance results obtained with different test methods. The DETECT trial metastatic breast cancer patients was designed to directly compare prognostic impact two commercially available CTC that are prominent representatives immunocytochemical and RT-PCR based technologies. Methods In total, 254 were enrolled in this prospective multicenter...
Abstract BACKGROUND The prognostic significance of isolated tumor cells (ITCs) in bone marrow (BM) from patients with breast carcinoma at the time their primary diagnosis recently was been confirmed by a large pooled analysis. If persistence ITCs after adjuvant therapy confers similar risk for recurrence, then it would be an indication to consider secondary therapy. METHODS authors analyzed BM aspirates 228 during recurrence‐free follow‐up median interval ± standard deviation (SD) 21.3 29.1...
Triple-negative (TN) breast cancer is an aggressive subtype of associated with a unique set epidemiologic and genetic risk factors. We conducted two-stage genome-wide association study TN (stage 1: 1529 cases, 3399 controls; stage 2: 2148 1309 controls) to identify loci that influence risk. Variants in the 19p13.1 PTHLH showed significant associations (P < 5 × 10−8) 1 2 combined. Results also suggested substantial enrichment significantly variants among single nucleotide polymorphisms (SNPs)...
<h3>Importance</h3> Circulating tumor cells (CTCs) represent the liquid component of solid tumors and are a surrogate marker for residual cancer burden. Although CTC status is prognostic recurrence death in breast cancer, its role guiding clinical management remains unknown. <h3>Objective</h3> To determine whether predictive radiotherapeutic benefit early-stage cancer. <h3>Design, Setting, Participants</h3> The cohort studies present analysis included patients with stages pT1 to pT2 pN0 pN1...
The prognostic relevance of circulating tumor cells (CTCs) at the time primary diagnosis has been well established. However, little information is available regarding their to follow-up care.The multicenter, open-label, phase III SUCCESS A trial compared two adjuvant chemotherapy regimens followed by 2 vs 5 years zoledronate for early-stage, high-risk breast cancer patients. presence CTCs was assessed before and after using FDA-approved CellSearch System. Overall survival (OS) disease-free...
Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable unclear. This retrospective analysis was performed using data from SUCCESS A trial, in 3754 with high-risk early were randomized to anthracycline- and taxane-based chemotherapy or without gemcitabine. Patients classified as underweight/normal (body mass index (BMI) < 25.0), overweight (BMI 25.0–29.9), slightly obese 30.0–34.9), moderately 35.0–39.9)...